EPEdvige Perrotti

Edvige Perrotti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Edvige Perrotti has a total of 77 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Alternate NF-κB-Independent Signaling Reactivation of Latent HIV-1 Provirus

    by Chiara Acchioni, Anna Lisa Remoli, Giulia Marsili, Marta Acchioni, Ilenia Nardolillo, Roberto Orsatti, Stefania Farcomeni, Enrico Palermo, Edvige Perrotti, Maria Letizia Barreca, et al.

    Current combination antiretroviral therapies (cART) are unable to eradicate HIV-1 from infected individuals because of the establishment of proviral latency in long-lived cellular reservoirs. The shock-and-kill approach aims to reactivate viral replication from the latent state (shock) using latency-reversing agents (LRAs), followed by the elimination of reactivated virus-producing cells (kill) by specific therapeutics. The NF-κB RelA/p50 heterodimer has been characterized as an essential component of reactivation of the latent HIV-1 long terminal repeat (LTR). Nevertheless, prolonged NF-κB activation contributes to the development of various autoimmune, inflammatory, and malignant disorders. In the present study, we established a cellular model of HIV-1 latency in J-Lat CD4+ T cells that stably expressed the NF-κB superrepressor IκB-α 2NΔ4 and demonstrate that conventional treatments with bryostatin-1 and hexamethylenebisacetamide (HMBA) or ionomycin synergistically reactivated HIV-1 from latency, even under conditions where NF-κB activation was repressed. Using specific calcineurin phosphatase, p38, and MEK1/MEK2 kinase inhibitors or specific short hairpin RNAs, c-Jun was identified to be an essential factor binding to the LTR enhancer κB sites and mediating the combined synergistic reactivation effect. Furthermore, acetylsalicylic acid (ASA), a potent inhibitor of the NF-κB activator kinase IκB kinase β (IKK-β), did not significantly diminish reactivation in a primary CD4+ T central memory (TCM) cell latency model. The present work demonstrates that the shock phase of the shock-and-kill approach to reverse HIV-1 latency may be achieved in the absence of NF-κB, with the potential to avoid unwanted autoimmune- and or inflammation-related side effects associated with latency-reversing strategies. IMPORTANCE The shock-and-kill approach consists of the reactivation of HIV-1 replication from latency using latency-reversing agents (LRAs), followed by the elimination of reactivated virus-producing cells. The cellular transcription factor NF-κB is considered a master mediator of HIV-1 escape from latency induced by LRAs. Nevertheless, a systemic activation of NF-κB in HIV-1-infected patients resulting from the combined administration of different LRAs could represent a potential risk, especially in the case of a prolonged treatment. We demonstrate here that conventional treatments with bryostatin-1 and hexamethylenebisacetamide (HMBA) or ionomycin synergistically reactivate HIV-1 from latency, even under conditions where NF-κB activation is repressed. Our study provides a molecular proof of concept for the use of anti-inflammatory drugs, like aspirin, capable of inhibiting NF-κB in patients under combination antiretroviral therapy during the shock-and-kill approach, to avoid potential autoimmune and inflammatory disorders that can be elicited by combinations of LRAs.


  • Open Access

    HIV-1 Tat Recruits HDM2 E3 Ligase To Target IRF-1 for Ubiquitination and Proteasomal Degradation

    by Anna Lisa Remoli, Giulia Marsili, Edvige Perrotti, Chiara Acchioni, Marco Sgarbanti, Alessandra Borsetti, John Hiscott, Angela Battistini

    In addition to its ability to regulate HIV-1 promoter activation, the viral transactivator Tat also functions as a determinant of pathogenesis and disease progression by directly and indirectly modulating the host anti-HIV response, largely through the capacity of Tat to interact with and modulate the activities of multiple host proteins. We previously demonstrated that Tat modulated both viral and host transcriptional machinery by interacting with the cellular transcription factor interferon regulatory factor 1 (IRF-1). In the present study, we investigated the mechanistic basis and functional significance of Tat−IRF-1 interaction and demonstrate that Tat dramatically decreased IRF-1 protein stability. To accomplish this, Tat exploited the cellular HDM2 (human double minute 2 protein) ubiquitin ligase to accelerate IRF-1 proteasome-mediated degradation, resulting in a quenching of IRF-1 transcriptional activity during HIV-1 infection. These data identify IRF-1 as a new target of Tat-induced modulation of the cellular protein machinery and reveal a new strategy developed by HIV-1 to evade host immune responses.IMPORTANCECurrent therapies have dramatically reduced morbidity and mortality associated with HIV infection and have converted infection from a fatal pathology to a chronic disease that is manageable via antiretroviral therapy. Nevertheless, HIV-1 infection remains a challenge, and the identification of useful cellular targets for therapeutic intervention remains a major goal. The cellular transcription factor IRF-1 impacts various physiological functions, including the immune response to viral infection. In this study, we have identified a unique mechanism by which HIV-1 evades IRF-1-mediated host immune responses and show that the viral protein Tat accelerates IRF-1 proteasome-mediated degradation and inactivates IRF-1 function. Restoration of IRF-1 functionality may thus be regarded as a potential strategy to reinstate both a direct antiviral response and a more broadly acting immune regulatory circuit.


  • IFN Regulatory Factors and Antiviral Innate Immunity: How Viruses Can Get Better

    by Giulia Marsili, Edvige Perrotti, Anna Lisa Remoli, Chiara Acchioni, Marco Sgarbanti, Angela Battistini

    The interferon regulatory factor (IRF) family consists of transcriptional regulators that exert multifaceted and versatile functions in multiple biological processes. Their crucial role as central mediators in the establishment and execution of host immunity in response to pathogen-derived signals downstream pattern recognition receptors (PRRs) makes IRFs a hallmark of the host antiviral response. They function as hub molecules at the crossroad of different signaling pathways for the induction of interferon (IFN) and inflammatory cytokines, as well as of antiviral and immunomodulatory genes even in an IFN-independent manner. By regulating the development and activity of immune cells, IRFs also function as a bridge between innate and adaptive responses. As such, IRFs represent attractive and compulsive targets in viral strategies to subvert antiviral signaling. In this study, we discuss current knowledge on the wide array of strategies put in place by pathogenic viruses to evade, subvert, and/or hijack these essential components of host antiviral immunity.


  • Type I IFN – A blunt spear in fighting HIV-1 infection

    by Chiara Acchioni, Giulia Marsili, Edvige Perrotti, Anna Lisa Remoli, Marco Sgarbanti, Angela Battistini


  • Open Access

    IκB Kinase ε Targets Interferon Regulatory Factor 1 in Activated T Lymphocytes

    by Marco Sgarbanti, Giulia Marsili, Anna Lisa Remoli, Emilia Stellacci, Antonello Mai, Dante Rotili, Edvige Perrotti, Chiara Acchioni, Roberto Orsatti, Nunzio Iraci, et al.

    IκB kinase ε (IKK-ε) has an essential role as a regulator of innate immunity, functioning downstream of pattern recognition receptors to modulate NF-κB and interferon (IFN) signaling. In the present study, we investigated IKK-ε activation following T cell receptor (TCR)/CD28 stimulation of primary CD4+ T cells and its role in the stimulation of a type I IFN response. IKK-ε was activated following TCR/CD28 stimulation of primary CD4+ T cells; however, in T cells treated with poly(I·C), TCR/CD28 costimulation blocked induction of IFN-β transcription. We demonstrated that IKK-ε phosphorylated the transcription factor IFN regulatory factor 1 (IRF-1) at amino acid (aa) 215/219/221 in primary CD4+ T cells and blocked its transcriptional activity. At the mechanistic level, IRF-1 phosphorylation impaired the physical interaction between IRF-1 and the NF-κB RelA subunit and interfered with PCAF-mediated acetylation of NF-κB RelA. These results demonstrate that TCR/CD28 stimulation of primary T cells stimulates IKK-ε activation, which in turn contributes to suppression of IFN-β production.


  • IRF-7: an Antiviral Factor and Beyond

    by Edvige Perrotti, Giulia Marsili, Marco Sgarbanti, Anna Lisa Remoli, Alessandra Fragale, Chiara Acchioni, Roberto Orsatti, Angela Battistini


  • HIV-1, interferon and the interferon regulatory factor system: An interplay between induction, antiviral responses and viral evasion

    by Giulia Marsili, Anna Lisa Remoli, Marco Sgarbanti, Edvige Perrotti, Alessandra Fragale, Angela Battistini


  • HIV-1 Targeting of IFN Regulatory Factors

    by Anna Lisa Remoli, Giulia Marsili, Marco Sgarbanti, Edvige Perrotti, Alessandra Fragale, Roberto Orsatti, Angela Battistini


  • PS1-095 Deregulation of I-kappa-B kinase epsilon (IKK-ε) in breast cancer: & #8232;effects on IRF1 activity

    by Giulia Marsili, Marco Sgarbanti, Anna Lisa Remoli, Edvige Perrotti, Chiara Acchioni, Angela Battistini

  • PS2-066. Role Of Irf-7 And Irf-1 In Lmp2 Transcription Stimulation In Human Myeloid Dendritic Cells

    by Edvige Perrotti, Marco Sgarbanti, Anna Lisa Remoli, Alessandra Fragale, Emilia Stellacci, Giulia Marsili, Angela Battistini